Our recent work has shown that theophylline which inhibits intracellular cyclic adenosine monophosphate (cAMP) degradation is able to kill chronic lymphocytic leukemia (CLL) cells in vitro and synergizes in vitro and in vivo with chlorambucil. In order to test the hypothesis that theophylline works through an indirect increase in cAMP, we have investigated the role of several molecules on B-CLL cells from 20 patients. Direct cAMP inducers such as dibutyryl-cAMP (db-cAMP), prostaglandin-E2 (PGE2) and forskolin induced moderate apoptosis but extremely high levels of intracellular cAMP. By contrast theophylline was highly apoptotic but did not synergize with cAMP inducers. Apoptosis was completely reversed by a cAMP antagonist when induced by PGE2 or forskolin, but was only partially antagonized when induced by theophylline. Since CD38 + CLL cells are more sensitive to apoptosis and since CD38 is enhanced by cAMP inducing agents its expression was investigated. In our hands CD38 was not induced by the above pharmacological compounds. Exogenous IL-10 has been shown to induce CLL cell death; however, apoptosis following treatment with theophylline or cAMP inducers could not be ascribed to endogenous production of IL-10. This ruled out the involvement of cytokines or of an activation or differentiation process in apoptosis. Altogether our data show that an increase in intracellular cAMP mediates apoptosis in vitro but accounts only partly for theophylline-mediated apoptosis.
Introduction
Apoptosis or programmed cell death (PCD) is a physiological mechanism involved in the selection and differentiation of lymphocytes, especially B cells. 1 Conversely defective apoptosis is associated with tumorigenesis, including in B cell malignancies. 2, 3 Thanks to recent techniques it has become possible to study the effect of various pharmacological agents on PCD in vitro. Indeed chlorambucil a classical active drug in the treatment of CLL was shown to induce PCD in cultured leukemic cells. 4 Based on clinical 5 and experimental data, 5, 6 we have previously demonstrated the potent induction of PCD on CLL cells by the methylxanthine derivative, theophylline. This compound was also shown to synergize in vitro and in vivo with chlorambucil for the induction of PCD. 6 Theophylline has long been known to inhibit phosphodiesterase activity thus avoiding the degradation of cAMP into AMP. Although the mechanism of theophylline-induced PCD on CLL cells remains poorly understood, an indirect augmentation of intracellular cAMP is thought to account for the pharmacological effect of theophylline. It is worth mentioning that an increase in intracellular cAMP mediates PCD in resting B cells 7 and germinal center B cells 8 as well as in T cells 9 supposed that cAMP-inducing agents would have the same apoptotic effect as theophylline on CLL cells. Conversely, pharmacological inhibition of cAMP should reverse PCD under the same conditions. Cells from 20 CLL patients were stimulated with the following agents: anti-IgM, theophylline, cAMP inducers prostaglandin E2 (PGE2) and forskolin and a cAMP-permeating analog dibutyryl-cAMP (db-cAMP). Cultures were performed with or without the cAMP inhibitor RPcAMP. We also searched for a synergy on apoptosis and/or cAMP production between theophylline and cAMP-inducers. Intracellular cAMP and PCD were assayed quantitatively in parallel in search for a correlation between cAMP and PCD. We also investigated whether the above pharmacological compounds triggered apoptosis indirectly by inducing the production of TNF-␣ or interleukin-10 (IL-10), for instance from bystander cells which would kill B-CLL cells. Indeed PGE2 and db-cAMP have been shown to induce an early production of TNF-␣ by monocytes followed by secondary production of IL-10. 11 The production of IL-10 which has been reported to induce the apoptosis of CLL cells 12 was therefore assayed. The phenotype of B-CLL cells was analyzed since apoptosis could be linked to an activation/differentiation process 1 which can be traced by membrane expression of activation markers. In particular we looked for an upregulation of CD38, a lymphocyte activation marker endowed with ectoenzymatic activity 13 previously shown in our laboratory to be induced by db-cAMP.
14 A recent work reported that B-CLL could fall into two subgroups: CD38-negative and CD38-positive, the latter showing a greater propensity for apoptosis. 15 This prompted us to look to whether cAMP inducers upregulated membrane CD38 expression in B-CLL. We also investigated the role of cAMP inducers in the expression of CD81 since this antigen is associated with the BCR transduction complex with a potential role in B cell activation. 16 Altogether our results confirm the potency of theophylline and to a lesser extent of cAMP-inducing agents to trigger PCD in B lymphocytes from patients with CLL. The fact that the levels of intracellular cAMP did not strictly correlate with PCD makes unlikely the initial hypothesis that an increase in cAMP is the only mechanism accounting for theophylline-mediated apoptosis.
Materials and methods

Cell culture
Blood samples were obtained from 29 
Intracellular cyclic AMP measurement
Cells were incubated with various compounds at 2.5 × 10 6 /ml for 0, 15 or 30 min. 0.1 ml were centrifuged, washed twice in PBS, resuspended in PBS, frozen in liquid nitrogen and thawed in a water bath. After three cycles of freezing/thawing, extracts were harvested at −20°C until assay. The cAMP measurement was done by ELISA using the Biotrak cAMP EIA system (Amersham, Buckinghamshire, UK).
Cell apoptosis
In situ apoptosis detection kit (Boehringer Mannheim) based on the TUNEL method was used for quantitative analysis. 1000 cells/patient were fixed on slides and counted on microscope and % of positive (apoptotic) cells recorded as described. 6 Apo 2.7 PE antibody (Immunotech, Marseille, France) was used to detect apoptosis by flow cytometry. Unpermeabilized cells cultured in various conditions were stained with Apo 2.7 following the manufacturer's instructions and analyzed at 6, 12, 24 and 48 h.
Immunostaining procedures and analysis
Cells were incubated at 4°C with the following Mabs at concentrations recommended by the manufacturers: anti-CD81 isotype match mouse IgG2a and goat anti-mouse-PE (all from Coulter/Immunotech, Marseille, France), CD5-FITC/CD19-PE (Dako) CD38-PE Leu 17 (Becton Dickinson, San Jose, CA, USA).
Cytokine assays
Supernatants from cells cultured at 1 × 10 6 /ml in various conditions were harvested at 48 h, frozen at −20°C and assayed for content in IL-10 and TNF-␣ using ELISA kits (Innotest, Besançon, France).
Results
Correlation between intracellular cAMP levels and % of apoptotic CLL cells following treatment with cAMPinducing agents
Having recently shown that apoptosis can be mediated in vitro by theophylline, we analyzed the effects of agents known to induce intracellular production of cAMP on cells from 20 patients with CLL (Ͼ90% B cells).
The dUTP nick end labeling (TUNEL) technique was used to quantitate apoptosis and the % of apoptotic cells counted on glass slides as described previously. 6 Results are shown at 48 h since PCD reached a plateau between 48 and 72 h as assessed by our previous kinetic analysis. As shown in Figure 1 (bottom panel), spontaneous apoptosis (control) reached 22% with variations from 5% to 62%.
A significant effect was obtained however with anti-IgM as compared to control: mean apoptosis 58% with very wide individual variations in response ranging from 2% (no response) to 90% as expected from our previous data. 6 To determine the effect of endogenous cAMP on apoptosis, cells were incubated with increasing concentrations of PGE2 and % of apoptotic cells (Figure 1 , bottom) and intracellular c-AMP concentrations (Figure 1 , top) were measured in parallel. PGE2 was used at concentrations ranging from 1 nM to 1000 nM. Apoptosis was significant from 10 nM, was dosedependent and reached a plateau at 41% apoptosis from a concentration of 100 nM PGE2 which was as efficient as 1000 nM PGE2 (Figure 1, bottom) .
Contrary to anti-IgM, the effect of PGE2 was observed on every sample tested. PGE2-induced apoptosis was mediated only by cAMP as shown from the ability of the cAMP inhibitor RP-cAMP at 0.1 mM to reverse completely the effect of 100 nM of PGE2 on CLL cells (Figure 1, bottom) . Note that RP-cAMP had no toxic effect by itself on cell survival. Intracellular cAMP was assayed in parallel in the same culture conditions but after a short incubation. In our hands, maximum concentrations were obtained after 30 min incubation of the cells. Figure 1 (top) shows that cAMP levels increased in parallel with the concentration of PGE2 to 1000 nM. Since % apoptosis did not differ between 100 nM and 1000 nM PGE2 increasing intracellular cAMP above 3800 fM/ml did not augment apoptosis. Thus, above a given concentration cells become refractory to cAMP inducers. Of note, because RPcAMP crossreacts with anti-cAMP Abs, cAMP in cells treated with PGE2 + RP-cAMP cannot be measured by ELISA assay.
Theophylline-mediated apoptosis is both cAMPdependent and independent
We next investigated in a separate experiment the effect of theophylline vs cAMP inducers (Figure 2 , bottom) and measured in parallel cAMP (Figure 2, top) . Theophylline at 0.1 mM induced PCD in every case of the 20 samples tested (mean 76% of apoptosis).
The effects of direct cAMP inducers were compared to that of theophylline. db-cAMP has the unique property, contrary to its analog cAMP, to enter the cell. In our hands, 100 M of db-cAMP induced PCD in all samples tested (mean 41%). This effect was significantly higher than control but lower than theophylline-mediated PCD.
The same effect was obtained with 100 M forskolin, the most potent cAMP inducer. Indeed, forskolin-mediated PCD was significant in all samples as compared to control (mean 49%), but was nonetheless weaker than that of theophylline. Thus both direct and indirect inducers of cAMP were potent in vitro killers of CLL cells (Figure 2, bottom) .
To gain further insight into the role of cAMP in PCD, B-CLL cells were preincubated with a pharmacological analog of cAMP, RP-cAMP which binds to protein kinase A thus inhibiting the effect of cAMP. While RP-cAMP was able to block completely forskolin and PGE2-mediated PCD which returned to control levels, it blocked only one third of theophylline-mediated PCD. Indeed theophylline-induced PCD dropped only to 56% with RP-cAMP from 76% without RP-cAMP. These results suggested that high endogenous levels of cAMP accounted completely for the effect of forskolin and PGE2 but only partly for the effect of theophylline. We therefore expected a lack of synergy between theophylline and forskolin or PGE2. Indeed apoptosis was similar in cells cultured with theophylline alone vs theophylline + PGE2 or theophylline + forskolin at 76, 79 and 78%, respectively (Figure 2,  bottom) .
Finally an augmentation in cAMP levels was not observed when theophylline was added to forskolin (Figure 2 , top) as compared to forskolin alone. Conversely apoptosis reached a maximum with theophylline alone and was not augmented by a combination of theophylline and forskolin. From the above data we conclude: (1) that increasing cAMP above a given concentration did not augment apoptosis; and (2) that cAMP is not the only mechanism accounting for theophyllinemediated PCD.
Theophylline and cAMP-mediated PCD in B-CLL is independent of a B cell activation and/or differentiation process
We next examined whether cAMP-mediated PCD was associated with modifications of surface markers (Figure 3 ) which would in turn trigger cell death through receptor engagement. 1 The activation marker CD38 was reported to be present in about one-third of cells from CLL 15 with a weaker signal transduction capacity and a higher propensity for antiIgM-mediated apoptosis. Importantly we have previously shown the ability of cAMP inducers to increase CD38 on Jurkat cells 13, 14 the same property was therefore investigated in CLL cells. Out of 10 samples tested, two were found to be strongly positive and one had intermediate expression for CD38 (not shown). In all three cases however there was no modification in surface CD38 after 24-48 h culture. Two representative samples, one positive, and one negative, are shown in Figure 3 . In both cases, there was no difference between control and stimulated cells showing that CD38 was neither induced nor enhanced in our culture conditions which were nonetheless sufficient to induce CD38 expression on a CD38 dull subclone of the control HPB-ALL T cell line. 14 In addition to CD5 and CD19, CD81 expression which is present on B lymphocytes and is increased in activated cells from germinal centers 17 was investigated in parallel. Of interest CD81 is associated with a B cell transduction complex including CD19 16, 18 and is therefore associated with B cell activation. We found that while CD5 and CD19 expression remained stable CD81 expression was moderately induced by both theophylline and cAMP-inducers (Figure 3) . Of note, all nine samples examined were negative for CD81 before incubation with theophylline or with PGE2, db-cAMP or forskolin.
To make sure that stimulated cells were undergoing apoptosis at the time of staining, they were incubated with the mitochondrial marker Apo 2.1. Apoptosis was also shown by the aspect of treated cells on forward/side scatter analysis which, contrary to controls, showed a shrinkage in size of the cell population (Figure 3 ).
In conclusion our data failed to show a clearcut modification of activation surface markers following theophylline/cAMP-treated cells except for a modest increase in CD81.
Lack of correlation between apoptosis and endogenous IL-10 or TNF-␣ production in CLL
To determine if cAMP mediated PCD directly or indirectly through production of 'apoptotic' cytokines, the production of IL-10 which have been shown to induce cell death of B-CLL cells 12 was measured in supernatants from cells treated with various cAMP inducers or inhibitors or with theophylline. No significant increase in the production of IL-10 was noticed following stimulation with either cAMP-inducers or theophylline. The same conclusions apply for the production of TNF-␣ ( Table 1 ). The latter cytokine is an early product of monocytes following stimulation with PGE2 or cAMP analogs. 11 A delayed production of IL-10 has also been observed under the same conditions. Our results however do not suggest an involvement of either IL-10 or TNF-␣ in B-CLL apoptosis.
Discussion
This work was initially performed to evaluate the role of cAMP in theophylline-induced apoptosis of B-CLL cells. We have shown that CLL cells undergo apoptosis in vitro following incubation with cAMP inducers. That cAMP is responsible for cell death is shown by the prevention of apoptosis when cells Table 1 Cytokine production by CLL cells under various conditions TNF␣ (pg/ml) IL-10 (pg/ml) B-CLL cells (10 6 /ml) were cultured for 48 h with medium alone or anti-IgM (10 g/ml) PGE2 (10 or 100 nM) dbcAMP or theophylline (0.1 mM). Supernatants in duplicates were harvested at −20°C and assayed for the presence of interleukin-10 and TNF␣ by EIA. Mean ± s.d. from 10 patients.
were pretreated with an antagonistic analog of cAMP. Previous studies have demonstrated that cAMP-inducing stimuli elicited apoptosis in B cells, 8 thymocytes 10 and myeloid cells. 19 Thus an elevation of cAMP seems to be a universal cell death signal at least for hematopoietic cells. Nevertheless there are several cAMP-dependent and -independent death pathways in B cells 7 and in B-CLL cells as shown by the lack of correlation between anti-IgM-induced PCD and cAMP production in our experiments.
Sensitivity to cAMP is however variable and we have previously shown that B-CLL cells were more sensitive by fivefold than normal B cells. 6 Daudi cell line was also resistant in our hands to apoptosis although very high doses of forskolin (1 mM) or of theophylline were effective (data not shown). The main finding in our study is that theophylline acts also through an as yet unknown, cAMP-independent mechanism. Interestingly, authors reported recently that theophylline induced apoptosis on neutrophils which was independent from phosphodiesterase inhibition. 20 To make sure that PCD was not due to ethylene diamine which is associated in most theophylline preparations, this molecule was investigated and failed to induce PCD at working concentrations (not shown).
Cross-linking of sIg or of BCR-associated antigens such as CD19 leads to the apoptotic demise of immature B cells and in contrast to the activation of germinal center B cells. 1 The variability of effects on CLL cells could not be ascribed to a particular phenotype and from our study was not linked to cAMP. Conversely we studied whether the effect of cAMP was linked to an activation process that could be traced by membrane expression of activation and BCR-associated molecules. Given the role of cAMP as a death signal in various lymphoid and myeloid cell lines and as an inducer of surface expression of CD38, we looked for the expression of this antigen on CLL cells. In keeping with previous results 13 we found that around 10% of our CLL patients had CD38-high or intermediate expression of CD38 on B-CLL. However CD38-positive cells were comparable to CD38-negative ones in their apoptotic response to theophylline or to direct cAMP inducers. Thus although CD38
+ cells have a higher propensity for spontaneous or anti-SIg-mediated apoptosis (Ref. 13 and our unpublished data) cAMP and theophylline-mediated PCD in our model could not be ascribed to an increase in surface CD38. Contrary to what we have found in normal T cells and T cell lines 14, 15 as well as what we have observed in myeloid cell lines (not shown) CLL cells did not upgrade surface CD38 following treatment with cAMP inducers. This is in contrast to the effect of IFN-␣, IFN-␥, or TPA which were shown to induce terminal differentiation of CLL cells together with an induction of surface T10 antigen known as CD38. 21 We also hypothesized that PCD was mediated through upregulation of surface markers such as CD19 or CD81 which amplify the signal transduced by the antigen-receptor complex. 18 Such a signal is often impaired in CLL cells unresponsive to sIg cross-linking owing to abnormal tyrosine phosphorylation of various substrates including syk, as we have shown recently. 22 In our hands, theophylline or cAMP inducers failed to modify the surface expression of CD19 or CD5. A modest increase in the expression of CD81 was however noticed after treatment with either theophylline or PGE2. Thus our data do not suggest that apoptosis was linked to an activation process. This is in contrast with data showing that IFN-␥ induced concomitant apoptosis and CD38 expression on B-CLL. 31 Exogenous IL-10 was shown to be deleterious on the viability of CLL cells but not on that of other malignant B cells. 11 We showed that theophylline did not enhance the production of IL-10 in our cultures (Table 1) . We have previously shown that contrary to IL-10, IL-4 protects CLL cells from theophylline or chlorambucil-induced PCD. 6 It is worth mentioning that triggering CD81 in normal B cells enhances IL-4 synthesis by CD4
+ cells in a coculture system. 23 Antibody binding of CD81 induces growth inhibition of B cell lines consistent with the role of this antigen in signaling and cell proliferation. The role of this molecule in CLL cells is under study. Altogether our data do not favor the hypothesis that cAMP or theophylline induced apoptosis through production of cytokines from bystander cells.
Our results not only show the direct effect of cAMP inducers on apoptosis of CLL but also the superiority of theophylline over direct cAMP inducers used in this study. Indeed, theophylline acted through enhanced production of cAMP and mostly through a cAMP-independent apoptotic mechanism. In our quest for such a mechanism we failed to show a clearcut role for a cytokine or a surface antigen. Methylxanthines such as caffeine and pentoxyfylline have long been known to enhance the cytotoxicity of alkylating agents 24 and of x-irradiation and anticancer drugs in cell culture. 25 Methylxanthines synergize with alkylating agents possibly by preventing delays in the cell cycle transit through the G-2 phase thus not allowing time for repair of DNA cross-links. 26 This might explain our finding of a synergy between theophylline and chlorambucil. 6 Although methylxanthines induced cAMP in monocytes they failed to enhance and instead inhibited the production of TNF-␣ by monocytes 27 in keeping with our results. However our data point out a direct effect of theophylline on apoptosis independently of any anti-cancer drug. Recently, authors demonstrated that purine analogs, 2-chlorodeoxyadenosine, 28 or fludarabine, 29 elicited apoptosis in B-CLL cells. Whether methylxanthine-mediated PCD is related to its purine structure is currently investigated. Since cAMP accounted only partly for this effect, molecular targets different from that induced by cAMP 30 must be explored.
